Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk (Q45288843)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 September 2011

Language	Label	Description	Also known as
English	Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk	scientific article published on 2 September 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

G protein-coupled receptor

0 references

0 references

0 references

cannabinoid receptor

0 references

metabolic disease

1 reference

based on heuristic

inferred from title

Alexandros Makriyannis

4

object named as

Alexandros Makriyannis

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

David R Janero

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Loren Lindsley

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Venkata Kiran Vemuri

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

2 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Expert Opinion on Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

995-1025

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Energy regulatory signals and food reward

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Obesity as a clinical and public health problem: is there a need for a new definition based on lipotoxicity effects?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Insulin, insulin resistance, obesity, and cancer

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Nonalcoholic fatty liver disease: pathology and pathogenesis

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Diabesity: therapeutic options

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Drug management of obesity--efficacy versus safety

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Pharmacological management of appetite expression in obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Update on newer antihypertensive medicines and interventions

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Navigating the choices for diabetes prevention

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Rimonabant: obituary for a wonder drug

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoid receptors: where they are and what they do.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Signal transduction of the CB1 cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Enzymatic pathways that regulate endocannabinoid signaling in the nervous system

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The endocannabinoid system and its relevance for nutrition.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The endocannabinoid system and gut-brain signalling.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Leptin-regulated endocannabinoids are involved in maintaining food intake

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The role of the endocannabinoid system in lipogenesis and fatty acid metabolism.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Presence of functional cannabinoid receptors in human endocrine pancreas

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Depolarization-induced release of endocannabinoids by murine dorsal motor nucleus of the vagus nerve neurons differentially regulates inhibitory and excitatory neurotransmission

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Oleoylethanolamide affects food intake and sleep-waking cycle through a hypothalamic modulation

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The brain endocannabinoid system in the regulation of energy balance

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoids, opioids and eating behavior: the molecular face of hedonism?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Activation of cannabinoid CB1 receptors induces glucose intolerance in rats.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Alterations in the hippocampal endocannabinoid system in diet-induced obese mice.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Sustained weight loss after Roux-en-Y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

FAAH deficiency promotes energy storage and enhances the motivation for food

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Dysregulation of the endocannabinoid system in obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Activation of the peripheral endocannabinoid system in human obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study).

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Triggering myocardial infarction by marijuana

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabis use and obesity and young adults

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The structure and function of G-protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Inverse Agonism at Serotonin and Cannabinoid Receptors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Label-free whole-cell assays: expanding the scope of GPCR screening

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

An essential role for constitutive endocytosis, but not activity, in the axonal targeting of the CB1 cannabinoid receptor.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at cholecystokinin-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Binding between a distal C-terminus fragment of cannabinoid receptor 1 and arrestin-2.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Differential inverse agonism at the human muscarinic M₃ receptor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The endocannabinoid system: a new target for the regulation of energy balance and metabolism

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Inhibitors of cannabinoid receptors and glucose metabolism

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Genome-wide expression profiling revealed peripheral effects of cannabinoid receptor 1 inverse agonists in improving insulin sensitivity and metabolic parameters

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

From endocannabinoid profiling to 'endocannabinoid therapeutics'.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

CB1 antagonists for obesity--what lessons have we learned from rimonabant?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

An overview of practical approaches for handling missing data in clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The critical role of the endocannabinoid system in emotional homeostasis: avoiding excess and deficiencies

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Involvement of CB1 cannabinoid receptors in emotional behaviour.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Depression-like phenotype following chronic CB1 receptor antagonism

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Subjective and physiological effects after controlled Sativex and oral THC administration

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The hope and fear of rimonabant

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Randomized, controlled, double-blind trial of taranabant for smoking cessation

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Risk factors for chronic depression--a systematic review

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Well-being of obese individuals: therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

End of the line for cannabinoid receptor 1 as an anti-obesity target?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Blood-brain barrier permeability considerations for CNS-targeted compound library design

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Targeting the brain--surmounting or bypassing the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Novel thioamide derivatives as neutral CB1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A neutral CB1 receptor antagonist reduces weight gain in rat.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Inverse agonism of cannabinoid CB1 receptors potentiates LiCl‐induced nausea in the conditioned gaping model in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Conditioned gaping in rats: a selective measure of nausea

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Cannabinoids and the gut: new developments and emerging concepts

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Why is the neurobiology of nausea and vomiting so important?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Inverse agonism and neutral antagonism at cannabinoid CB1 receptors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Inhibitory effects of SR141716A on G-protein activation in rat brain

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

G protein coupled receptors -in silico drug discovery and design

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Structure-based drug discovery and protein targets in the CNS.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

In vivo, in vitro and in silico methods for small molecule transfer across the BBB.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The [35S]GTPγS binding assay: approaches and applications in pharmacology

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

"Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Animal models of mood disorders: Recent developments.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Rodent models in depression research: classical strategies and new directions.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Role of PUFAs, the precursors of endocannabinoids, in human obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

HIV protease inhibitors and obesity

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Intestinal and anorectal motility and functional disorders

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

CB1 receptor antagonists for the treatment of nicotine addiction

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Hypertension in children: new trends and challenges

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

The biotin connection: Severo Ochoa, Harland Wood, and Feodor Lynen

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Phase III and submission failures: 2007–2010

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2011.608063

21 January 2018

Identifiers

10.1517/17460441.2011.608063

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45288843&oldid=2073640244"